Vaccinex (VCNX) AI Stock Analysis

• Market Cap: $1.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.26
• Revenue Growth: 5.44%
• EPS Growth: 84.28%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,676,637
• 10 Day Avg. Volume: 776
• 30 Day Avg. Volume: 1,224
• PEG Ratio: <0.01
• Price to Book (P/B): -0.83
• Price to Sales (P/S): 3.42
• P/FCF Ratio: -0.13
• Enterprise Value/Market Cap: 4.05
• Enterprise Value/Revenue: 9.26
• Enterprise Value/Gross Profit: 9.70
• Enterprise Value/Ebitda: -0.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $0.50 ▲(4.17% Upside)

The overall stock score is heavily influenced by the company's poor financial performance and weak technical indicators. The negative P/E ratio and lack of dividend yield further underscore the stock's unattractiveness. Without any positive guidance or sentiment from earnings calls or notable corporate events, the stock remains a high-risk investment.

Vaccinex Business Overview & Revenue Model

Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

How the Company Makes Money

Vaccinex generates revenue through a combination of research and development partnerships, grants, and potential future product sales. The company often collaborates with larger pharmaceutical firms, which may provide funding in exchange for rights to co-develop or commercialize its therapeutic candidates. Additionally, Vaccinex may receive milestone payments and royalties based on the successful progression of its drug candidates through various stages of clinical development and eventual market approval. Government grants and awards for research initiatives also contribute to its funding, supporting ongoing development efforts.

Vaccinex Financial Statement Overview

Summary

Vaccinex operates in a challenging financial position with sustained losses and negative equity. While there is slight revenue growth, the financial instability, reflected in negative margins and cash flows, presents significant risks. The reliance on external financing adds to the company's precarious financial health.

Income Statement

The company shows poor profitability with persistent negative net income and EBIT margins. Although there was a slight increase in revenue from 2023 to 2024, the company is still operating at a loss. The revenue growth rate is positive, but the overall trend of high expenses and significant losses overshadows this growth.

Balance Sheet

The company's balance sheet is weak, characterized by negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is negative, highlighting financial instability and potential risk.

Cash Flow

Cash flow statements show negative operating and free cash flow, indicating the company is burning cash. However, financing cash flows have been positive, providing some liquidity relief. The free cash flow to net income ratio is not improving significantly, reflecting ongoing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	601.00K	570.00K	100.00K	900.00K	50.00K
Gross Profit	601.00K	570.00K	68.00K	731.00K	48.00K
EBITDA	-18.54M	-19.75M	-19.61M	-21.40M	-28.05M
Net Income	-18.63M	-20.25M	-19.72M	-22.38M	-28.85M
Balance Sheet
Total Assets	2.60M	3.63M	7.98M	9.84M	11.70M
Cash, Cash Equivalents and Short-Term Investments	1.11M	1.53M	6.39M	8.59M	10.60M
Total Debt	25.00K	247.00K	485.00K	390.00K	9.21M
Total Liabilities	5.08M	5.94M	2.78M	2.43M	14.31M
Stockholders Equity	-2.49M	-2.31M	5.19M	7.41M	-26.57M
Cash Flow
Free Cash Flow	-16.21M	-17.30M	-19.17M	-25.33M	-28.94M
Operating Cash Flow	-16.19M	-17.23M	-19.07M	-25.30M	-28.65M
Investing Cash Flow	-22.00K	-67.00K	-99.00K	-32.00K	-290.00K
Financing Cash Flow	15.78M	12.45M	16.98M	23.32M	36.76M

Vaccinex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 0.48 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.61, and below the 200-day MA of 0.78, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 34.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.

Vaccinex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOVX	45 Neutral	$10.03M	-0.02	-154.46%	―	―	61.74%
VCNX	39 Underperform	$1.38M	-0.05	1406.28%	―	5.44%	84.28%
AZTR	38 Underperform	$2.54M	-0.08	-473.31%	―	-100.00%	95.01%
GTBP	34 Underperform	$6.57M	-0.15	-181.99%	―	―	46.96%
REVB	28 Underperform	$2.57M	-0.02	-118.88%	―	―	96.26%